Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to find out whether the drug uproleselan can help patients with severe COVID-19 pneumonia. Investigators will study both the side effects of the drug and assess if the drug will help patients recover more quickly and slow down the progression of acute respiratory failure.


Clinical Trial Description

Soluble E-selectin is a significant biomarker for ARDS. Soluble E-selectin also has pro-inflammatory properties further releasing cytokines and promoting its synthesis and the continued influx of neutrophils. Small molecule glycomimetic antagonists of E-selectin (rivipansel and uproleselan) are 500- to 1000-fold more potent inhibitors of E-selectin and have shown activity and no measurable toxicity in human clinical trials for other indications. Treatment with these E-selectin inhibitors reduced the levels of soluble E-selectin in the bloodstream which occurs during recovery of ARDS. Thus antagonists of E-selectin which include glycomimetic antagonists and more specifically, rivipansel (GMI-1070) and uproleselan (GMI-1271), may be used to treat COVID-19 patients with respiratory symptoms that may lead to ARDS Primary Objective: Safety of uproleselan in patients with severe COVID-19 pneumonia. Secondary Objectives: To evaluate if treatment with uproleselan administered intravenously in addition to the best available therapy according to institutional guidelines is able to reduce the progression of acute respiratory failure, in patients with severe COVID-19 pneumonia. - To evaluate proportion of patients alive and free of respiratory failure through Day 28 - To evaluate overall survival and all-cause mortality at day 15 and 28. - To evaluate changes in the COVID ordinal outcomes scale. - To assess adverse events to evaluate the safety of uproleselan. - To assess ventilator-free days, ICU-free days, oxygen, vasopressor free days. - To evaluate changes in D-dimer. Exploratory Objectives: - To examine the correlation of plasma soluble E-selectin concentrations with clinical outcomes. - To examine the correlations of other biomarkers of interest with clinical outcome. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05057221
Study type Interventional
Source University of Michigan
Contact Jane Wong
Phone 734-936-4212
Email [email protected]
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date September 2021
Completion date September 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04901676 - Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04534478 - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Phase 4
Active, not recruiting NCT05002517 - Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Phase 3
Recruiting NCT05008393 - Efficacy of PJS-539 for Adult Patients With COVID-19. Phase 2
Recruiting NCT04569877 - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia Phase 2
Not yet recruiting NCT05045937 - Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19
Not yet recruiting NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Not yet recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Active, not recruiting NCT04615429 - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19 Phase 2
Recruiting NCT05047653 - RALE Versus CORADS/CT-Severity Score in COVID-19
Recruiting NCT05047016 - Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY N/A
Recruiting NCT05033847 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 3
Active, not recruiting NCT05035524 - A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19 N/A
Not yet recruiting NCT04390217 - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia Phase 2
Withdrawn NCT04460105 - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia Phase 1
Not yet recruiting NCT04918875 - Oxygen Requirements and Use in Patients With COVID-19 in LMICs
Not yet recruiting NCT05065879 - Evaluation of Immunogenicity and Safety of COVAX (Produced in Beijing) in Patients With Hypertension and/or Diabetes Phase 4
Not yet recruiting NCT05069129 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 3
Not yet recruiting NCT05077917 - Cromolyn Sodium for Treatment of COVID-19 Pneumonia Phase 3
Not yet recruiting NCT05065892 - Evaluation of Immunogenicity and Safety of COVAX (Produced in Wuhan) in Patients With Hypertension and/or Diabetes Phase 4